Loading company
Bioventus Inc.
BVS · Nasdaq · ·
Next earnings: November 3, 2026
$14.01-0.1%Sep 29 close
- 1M
- +1.2%
- 6M
- +56.4%
- 1Y
- +109.4%
- 5Y
- -1.1%
BVS · Nasdaq · ·
Next earnings: November 3, 2026
$14.01-0.1%Sep 29 close
Bioventus Inc. is scheduled to report next on November 3, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending June 27, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 27, 2026 | 3 months toJun 28, 2025 | Change |
|---|---|---|---|
| Total Revenue | $153.2M | $147.7M | +3.76% |
| Profit | $33.4M | $7.5M | +348.33% |
| Profit per share | $0.47 | $0.11 | +327.27% |
| Free Cash Flow | $18.9M | $25.3M | -25.11% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
“Bioventus continued its positive momentum in the second quarter, with solid performance that positions us well for continued success in the second half of the year,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
Bioventus delivers clinically proven, cost-effective products that help people heal quickly and safely. Its mission is to make a difference by helping patients resume and enjoy active lives. The Innovations for Active Healing from Bioventus include offerings for Pain Treatments, Surgical Solutions and Restorative Therapies. Built on a commitment to high quality standards, evidence-based medicine and strong ethical behavior, Bioventus is a trusted partner for physicians worldwide.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Bioventus Inc.’s Item 2.02 8-K filed August 5, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Bioventus Inc. has no earnings call transcript available.